Our argument is strongly supported by our findings showing prominent nuclear YAP expression in ALK‐TKI‐resistant tumors compared with pretreatment tumors in ALK‐rearranged NSCLC patients (Fig 6). Here, YAP1 is linked to non-small cell lung carcinoma.